Category: Pharmaceuticals and Biotech
![Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform](https://cdn.nwe.io/files/x/9a/99/ba32f10d9b5c1778d257eb1e435e.jpg)
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
![Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations](https://cdn.nwe.io/files/x/9c/fa/e8904d58ed1afdc1114e65b8118f.jpg)
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.
![Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients](https://cdn.nwe.io/files/x/1d/40/63c32e3c26de828d6275327bc524.jpg)
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
![TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit](https://cdn.nwe.io/files/x/b5/2d/4877bef2c0711a852d101f526114.jpg)
At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.
![Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study](https://cdn.nwe.io/files/x/bb/c3/a621d6db9e47c2c12d23ea10b575.jpg)
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
![TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference](https://cdn.nwe.io/files/x/fd/81/5bf5ed009d49779034272a0fe0bf.jpg)
Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.
![Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease](https://cdn.nwe.io/files/x/3a/6e/3a0910e45df78c904e348a8048e9.jpg)
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
![TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article](https://cdn.nwe.io/files/x/6f/35/67f3714f135f0cb925f77936e91e.jpg)
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
![TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit](https://cdn.nwe.io/files/x/8e/c2/0307287a8fe27fbf597e9999918d.jpg)
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease.
![TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference](https://cdn.nwe.io/files/x/6c/67/9bbf2466e1e391622e9d2032a80e.jpg)
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.
![FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies](https://cdn.nwe.io/files/x/f5/46/182a1304b6e1525dc49726a8b92b.jpg)
Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.
![Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment](https://cdn.nwe.io/files/x/31/ea/b3bbd744a893c346807df027298a.jpg)
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'
![Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility](https://cdn.nwe.io/files/x/bd/9d/02fccd5e3e700ce036cd99b89f74.jpg)
The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies
![Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety](https://cdn.nwe.io/files/x/4b/41/9d8982cd31a7cf52bcf442a16dea.jpg)
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.